The approval of SAHA in 2006 for cutaneous T-cell lymphoma demonstrates that HDAC is a potential cancer therapeutic target, and that small molecule drugs targeting HDAC might be promising in a wide range of cancer types. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.